The Probiotic Duopoly Is Crumbling: Why Next-Gen Microbes Could Do More

Two bacterial genera, Lactobacillus and Bifidobacterium, account for over 70% of all probiotic research published between 2019 and 2024, yet together they represent less than 2-3% of total microbial biomass in the healthy adult gut. That mismatch sits at the center of a new review published in Gut Microbes by Cappella, Redaelli, Balzarotti, Scarcia, and colleagues, who argue that the field has been constrained by historical accident rather than biological logic, and that a new class of microbes is ready to step in.

Lactobacillus and Bifidobacterium dominate research for historical, not biological, reasons

The dominance of these two genera did not emerge from evidence that they are the most functionally important microbes in the adult gut. It emerged from three more pragmatic facts: both were found early in fermented foods, both earned favorable safety classifications (GRAS in the United States, QPS in Europe), and both are easy to culture and stabilize in commercial products. With roughly 8,800 PubMed publications on Lactobacillus and 3,500 on Bifidobacterium, research momentum has compounded for decades.

The clinical returns, however, have been modest. Meta-analyses covering 2012 to 2025 show that traditional Lactobacillus and Bifidobacterium probiotics reduce infant eczema risk by around 20% when given prophylactically during pregnancy or early infancy, but show no significant benefit for asthma, allergic rhinitis, or food allergy. For irritable bowel syndrome, the pooled relative risk sits at 0.79, which sounds promising until you notice the heterogeneity index: I²=72%, meaning the results vary so widely across trials that the average is almost meaningless. For inflammatory bowel disease, some multi-strain formulations help prevent ulcerative colitis relapse, but there is no convincing signal for Crohn's disease. For obesity-related dysbiosis, the effect on body weight and metabolic parameters is minimal.

How dysbiosis and allergic disease actually unfold at the microbial level

Understanding why traditional probiotics underperform requires a clearer picture of what goes wrong during dysbiosis. The authors describe a cascade: microbial diversity collapses, symbiotic taxa are lost, pathobionts overgrow, and the altered metabolic environment erodes the tight junctions that seal the intestinal epithelium. Increased gut permeability allows microbial products to leak into circulation, triggering systemic inflammation.

In allergic disease, this process skews the immune system toward a Th2-polarized profile while contracting the pool of regulatory T cells (Tregs), the cells responsible for immune tolerance. The gut microbiome's role in modulating these immune responses is well established: early-life microbial composition sets the immunological tone for years afterward, and reduced abundance of short-chain fatty acid (SCFA)-producing taxa correlates directly with higher risk of sensitization and pediatric atopic disease. Gut microbiota dysbiosis can disrupt mucosal immunological tolerance, creating the conditions for food allergy and asthma to take hold.

The key molecular mediators here are SCFAs, particularly butyrate, propionate, and acetate. These metabolites promote Treg differentiation and restrain Th2 responses. They are produced not by Lactobacillus or Bifidobacterium but overwhelmingly by obligate anaerobes that have, until recently, been almost entirely absent from commercial probiotics.

Next-generation probiotics target the microbes that actually do the work

The review introduces next-generation probiotics (NGPs) as a category selected on the basis of defined biological function rather than manufacturing convenience. These innovative therapeutics go beyond conventional dietary supplements, offering targeted delivery and personalized approaches that older probiotic formats cannot match.

Two candidates receive the most attention. Akkermansia muciniphila, a mucus-layer inhabitant, upregulates the tight-junction proteins claudin-5 and claudin-8 while downregulating the permeability-associated claudin-2. In a phase I/II clinical trial, pasteurized A. muciniphila improved lipid profiles, intestinal permeability, and insulin sensitivity in overweight and obese adults. Faecalibacterium prausnitzii, one of the most abundant bacteria in a healthy adult colon, restores ZO-1 and occludin expression, directly reducing permeability. Both taxa have fewer than 1,000 PubMed publications combined, a stark contrast to the tens of thousands accumulated by the legacy genera.

Other candidates highlighted include spore-forming Clostridia from clusters IV and XIVa, which induce colonic Foxp3+ Tregs and enhance TGF-beta production; Butyricicoccus pullicaecorum and Odoribacter splanchnicus, which exert barrier-protective effects via extracellular vesicles; and Bacteroides fragilis, whose polysaccharide A component promotes Treg differentiation through antigen-presenting cells. Escherichia coli Nissle 1917, an unusual non-anaerobic NGP candidate with decades of clinical data, protects against chemically induced mucosal permeability and maintains remission in ulcerative colitis. The review also notes that non-viable preparations, called postbiotics or parabiotics, offer advantages in stability and dosing consistency: pasteurized A. muciniphila, for instance, retains biological activity without the challenges of keeping live obligate anaerobes viable through manufacturing and shelf life.

Translating next-gen candidates into clinical products is genuinely hard

The authors are candid about the gap between biological promise and clinical reality. Most NGP candidates are obligate anaerobes, meaning they die on contact with oxygen. Culturing them at scale, stabilizing them in a deliverable form, and ensuring they survive gastric transit are all unsolved engineering problems. Regulatory pathways add another layer: live biotherapeutic products (LBPs), the regulatory category that NGPs fall into for therapeutic applications, require drug-like development timelines and costs that dwarf those for conventional probiotic supplements.

The clinical trial landscape compounds the problem. Most existing trials use symptom endpoints, such as patient-reported bloating or stool frequency, that are only loosely connected to the mechanistic targets NGPs are designed to hit. Determining the ideal intervention window, particularly in early life, remains an open question because studies on the precise timing of microbial changes and immune development are still lacking. Safety assessment for emerging candidates also requires extensive genomic and toxicological work before broad use can be considered. The challenges facing traditional probiotic genera hint at how much harder those challenges become when the organisms in question are obligate anaerobes with limited safety track records.

What a post-duopoly probiotic field might look like

Cappella and colleagues are not arguing that Lactobacillus and Bifidobacterium are useless. Lacticaseibacillus casei Shirota, for instance, stimulates dendritic cells and promotes both IL-12 and IL-10 signaling, with documented benefits in Japanese cedar-pollen allergy. Bacillus clausii spores survive gastric transit and show efficacy against acute pediatric diarrhea. The argument is more targeted: the near-exclusive focus on these genera has left the microbial taxa most relevant to adult immune and metabolic homeostasis almost entirely unstudied in the clinical context.

The path forward the authors sketch involves rationally designed microbial consortia, selected for complementary metabolic functions rather than commercial familiarity; non-viable derivatives that sidestep manufacturing constraints; and clinical trials redesigned around mechanistic endpoints like SCFA levels, Treg counts, and intestinal permeability markers. Whether regulatory agencies and manufacturers move quickly enough to match the biology is a different question, and the review leaves it open. What it does establish clearly is that the evidence base for the current probiotic market does not reflect the evidence base for what the gut microbiome actually needs.